Two drugs are better than one to start T2DM therapy

Abstract

Early and intensive glycaemic control protects patients with type 2 diabetes mellitus (T2DM) from the development of late cardiovascular complications. The authors of the VERIFY trial now show that a more durable attainment of HbA 1c \u2009<7% is observed by adding vildagliptin to metformin as starting therapy in newly diagnosed patients with T2DM.